INM News and Press, InMed Pharmaceuticals Inc. From 02/03/25

INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin Dose ranging studies completed Vancouver, British Columbia-...

Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson's...

2025-01-21 10:31:36 ET DENVER, Colo., Jan 21, 2025 ( 247marketnews.com )- These are some of the hottest trades following yesterday’s inauguration. Helius Medical (NASDAQ: HSDT ), a neurotechnology company focused on innovative neuromodulation therapies for balance and gai...

2025-01-21 08:57:35 ET DENVER, Colo., Jan 21, 2025 ( 247marketnews.com )- InMed Pharmaceuticals (NASDAQ: INM ) reported promising results from a long-term preclinical Alzheimer’s Disease (AD) study. INM-901 demonstrated a reduction in several markers of neuroinflammation, a k...

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL') mRNA profile showed a reduction of several key neuroinflammatory genes in the brain Vancouver, British C...